Selective pharmacologic activation of the p53-dependent pathway as a therapeutic strategy for hematologic malignancies

Cell Cycle

Volumn 5, Issue 1, 2006, Pages 39-42

  Stühmer, Thorsten ^a,b   Bargou, Ralf C ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b Department of Internal Medicine II ^*  (Germany)

Author keywords

Apoptosis; Hematologic cancer; Multiple myeloma; Nutlin 3; p53; Primary tumor cells

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN MDM2; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD DISEASE; CELL ISOLATION; DRUG SELECTIVITY; GENOTOXICITY; HEMATOLOGIC MALIGNANCY; HUMAN; MOLECULAR CLONING; PROTEIN FUNCTION; REVIEW; TUMOR; TUMOR CELL; WILD TYPE;

EID: 33645309656     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.1.2281     Document Type: Review

References (35)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10.
2. Vousden KH, Lu X. Live or let die: The cell's response to p53. Nat Rev Cancer 2002; 2:594-604.
3. Stommel JM, Wahl GM. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J 2004; 23:1547-56.
4. Oren M. Decision making by p53: Life, death and cancer. Cell Death Differ 2003; 10:431-42.
5. Erster S, Moll UM. Stress-induced p53 runs a direct mitochondrial death program: Its role in physiologic and pathophysiologic stress responses in vivo. Cell Cycle 2004; 3:1492-5.
6. Hainaut P, Hollstein M. p53 and human cancer: The first ten thousand mutations. Adv Cancer Res 2000; 77:81-137.
7. Onel K, Cordon-Cardo C. MDM2 and prognosis. Mol Cancer Res 2004; 2:1-8.
8. Peller S, Rotter V. TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance. Hum Mutat 2003; 21:277-84.
9. Küpper M, Joos S, von Bonin F, Daus H, Pfreundschuh M, Lichter P, Trümper L. MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: Results from single cell polymerase chain reaction and molecular cytogenetic studies. Br J Haematol 2001; 112:768-75.
10. Portier M, Molès JP, Mazars GR, Jeanteur P, Bataille R, Klein B, Theillet C. p53 and RAS gene mutations in multiple myeloma. Oncogene 1992; 7:2539-43.
11. Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993; 81:128-35.
12. Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T, Vegna ML, Guglielmi C, Mancini F, Giuliacci S, Sacchi A, Mandelli F, Foa R. p53 expression in B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis. Blood 1998; 91:4342-9.
13. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype and a poor prognosis. J Clin Oncol 2001; 19:1405-13.
14. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-8.
15. Barillé-Nion S, Barlogie B, Bataille R, Bergsagel PL, Epstein J, Fenton RG, Jacobson J, Kuehl WM, Shaughnessy J, Tricot G. Advances in biology and therapy of multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2003; 248-78.
16. Stühmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C, Theurich S, Cigliano L, Manz RA, Daniel PT, Bommert K, Vassilev LT, Bargou RC. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005; 106:3609-17.
17. Avet-Loiseau H, Li JY, Godon C, Morineau N, Daviet A, Harousseau JL, Facon T, Bataille R. P53 deletion is not a frequent event in multiple myeloma. Br J Haematol 1999; 106:717-9.
18. Drach J, Ackermann J, Kaufmann H, Königsberg R, Huber H. Deletions of the p53 gene in multiple myeloma. Br J Haematol 2000; 108:886.
19. Schultheis B, Kramer A, Wilier A, Hegenbart U, Goldschmidt H, Hehlmann R. Analysis of p73 and p53 gene deletions in multiple myeloma. Leukemia 1999; 13:2099-103.
20. Elnenaei MO, Gruszka-Westwood AM, A'Hern R, Matutes E, Sirohi B, Powles R, Catovsky D. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A. Haematologica 2003; 88:529-37.
21. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, Ruvolo V, Tsao T, Zeng Z, Vassilev LT, Andreeff M. MDM2 antagonists induce p53-dependent apoptosis in AML: Implications for leukemia therapy. Blood 2005; In press.
22. Bonadonna G, Viviani S, Bonfante V, Gianni AM, Valagussa P. Survival in Hodgkin's disease patients - Report of 25 years of experience at the Milan Cancer Institute. Eur J Cancer 2005; 41:998-1006.
23. van Leeuwen FE, Klokman WJ, van't Veer MB, Hagenbeek A, Krol ADG, Vetter UAO, Schaapveld M, van Heerde P, Burgers JMV, Somers R, Aleman BMP. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18:487-97.
24. Maggio EM, Stekelenburg E, Van den Berg A, Poppema S. TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein-Barr virus. Int J Cancer 2001; 94:60-6.
25. ARF overexpression in Reed-Sternberg cells in Hodgkin's Lymphoma. Am J Pathol 2002; 160:569-78.
26. ARF and p53 binding. Leuk Lymphoma 2003; 44:1587-96.
27. Treichel U. Analyse isolierter, individueller Tumorzellen des klassischen Hodgkin Lymphoms auf Mutationen im mdm2-Gen-Lokus. Dissertation http://www.diss.fu-berlin.de/2005/119/index.html.
28. Janz M, Stühmer T, Vassilev LT, Dörken B, Bargou RC. Activation of the p53 pathway by disruption of p53/MDM2 interaction efficiently induces apoptosis in Hodgkin cell lines. Onkologie 2005; 28:171.
29. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene 2004; 23:2797-808.
30. Schaffner C, Stilgenbauer S, Rappold GA, Döhner H, Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood 1999; 94:748-53.
31. Blagosklonny MV. Prospective strategies to enforce selectively cell death in cancer cells. Oncogene 2004; 23:2967-75.
32. Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 2005; 65:1918-24.
33. Vassilev LT. p53 activation by small molecules: Application in oncology. J Med Chem 2005; 48:4491-9.
34. Brachmann RK. p53 mutants. The Achilles' heel of human cancer? Cell Cycle 2004; 3:1030-4.
35. Blagosklonny MV. P53: An ubiquitous target of anticancer drugs. Int J Cancer 2002; 98:161-6.